MUSCLE RELAXANT AND ANALGESIC CAPLETS TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Compra

Scheda tecnica Scheda tecnica (SPC)
01-02-2010

Principio attivo:

IBUPROFEN; METHOCARBAMOL

Commercializzato da:

INTERNATIONAL PHARMACEUTICAL GENERICS LTD

Codice ATC:

M03BA53

INN (Nome Internazionale):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Dosaggio:

200MG; 500MG

Forma farmaceutica:

TABLET

Composizione:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

Via di somministrazione:

ORAL

Confezione:

100

Tipo di ricetta:

OTC

Area terapeutica:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

Dettagli prodotto:

Active ingredient group (AIG) number: 0248961001; AHFS:

Stato dell'autorizzazione:

CANCELLED PRE MARKET

Data dell'autorizzazione:

2017-06-13

Scheda tecnica

                                1 | P a g e
PRODUCT MONOGRAPH
MUSCLE RELAXANT & ANALGESIC CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
INTERNATIONAL PHARMACEUTICAL GENERICS LTD.,
Date of Preparation:
30 Malta Avenue, Suite 2408
February 01, 2010
Brampton, ON
L6Y 4S5
Control#: 135919
2 | P a g e
TABLE
OF CONTENTS
Clinical
Pharmacology..............................................................................................................................3
Indications:................................................................................................................................................7
Contraindications
......................................................................................................................................8
Warnings:..................................................................................................................................................8
Precautions..............................................................................................................................................12
Drug Interactions
....................................................................................................................................13
Adverse Reactions
..................................................................................................................................15
Symptoms and Treatment of
Overdose...................................................................................................17
Dosage and
Administration.....................................................................................................................18
Pharmaceutical
Information....................................................................................................................19
Composition:...........................................................................................................................................21
Availability of Dosage
Forms............
                                
                                Leggi il documento completo